Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma


ABSTRACT: Knowledge of essential oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells bearing an oncogenic mutation while sparing normal cells. Lenalidomide is emerging as an active agent in diffuse large B cell lymphoma (DLBCL), especially for the activated B cell-like (ABC) subtype, but the mechanism of its action is unknown. Here we show that lenalidomide kills ABC DLBCL cells by augmenting the production of interferon 3/4, which these cells are predisposed to produce by their oncogenic MYD88 mutations. Lenalidomide stimulates the type I interferon pathway by suppressing IRF4, a repressor of IRF7. IRF4 is required for ABC DLBCL viability and is both a target and an amplifier of NF-kB signaling in this lymphoma subtype. Blockade of B cell receptor (BCR) signaling synergized with lenalidomide to reduce IRF4 levels, increase interferon 3/4 secretion, decrease NF-kB, and kill ABC DLBCL cells, suggesting therapeutic combinations that exploit the oncogenic signaling pathways in this cancer. For the OCILY10 cell line treated with 10 uM lenalidamide, a four point time course of 3, 6, 24, and 48 hours was analyzed (n=4). For the TMD8 cell line treated with 10 uM lenalidamide, a four point time course of 3, 6, 24, and 48 hours was analyzed (n=4).

ORGANISM(S): Homo sapiens

SUBMITTER: Louis Staudt 

PROVIDER: E-GEOD-33012 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


Knowledge of oncogenic mutations can inspire therapeutic strategies that are synthetically lethal, affecting cancer cells while sparing normal cells. Lenalidomide is an active agent in the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), but its mechanism of action is unknown. Lenalidomide kills ABC DLBCL cells by augmenting interferon β (IFNβ) production, owing to the oncogenic MYD88 mutations in these lymphomas. In a cereblon-dependent fashion, lenalidomide downreg  ...[more]

Similar Datasets

2016-09-01 | E-GEOD-73281 | biostudies-arrayexpress
2012-08-16 | GSE33012 | GEO
2012-09-20 | E-GEOD-41034 | biostudies-arrayexpress
2011-07-01 | E-GEOD-22901 | biostudies-arrayexpress
2015-11-01 | E-GEOD-63029 | biostudies-arrayexpress
2010-12-30 | E-GEOD-22900 | biostudies-arrayexpress
2014-08-01 | E-GEOD-58791 | biostudies-arrayexpress
2009-06-01 | E-GEOD-11902 | biostudies-arrayexpress
2012-08-16 | GSE32456 | GEO
2010-05-27 | E-GEOD-10009 | biostudies-arrayexpress